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Abstract: A single intragastric administration of 7,12-dimethylbenz(a)anthracene (DMBA) has been shown to induce 
mammary tumors in young cycling female Sprague-Dawley rats. The appearance of the tumors is preceded, during the la-
tency phase, by a series of neuroendocrine disturbances, including attenuation of the preovulatory Luteinizing Hormone 
surge and Gonadotropin-Releasing Hormone release and amplification of the preovulatory 17 -Estradiol (E2) surge. 
Also, E2 treatment leads to a complete blunting of the Isoproterenol-induced stimulation of Melatonin secretion.In this 
study, we examined the hypothesis that Tamoxifen, an antagonist of E2, would stimulate the Isoproterenol-induced Mela-
tonin (MT) secretion from the pineal gland, during the latency phase.  
 Sprague-Dawley rats, 55-60 days of age, received, on the Estrous day of the Estrous cycle, a single dose of 15 mg DMBA 
delivered by intragastric intubation. In order to avoid possible interactions with endogenous steroids or mammary tumor-
derived compounds, they were ovariectomized 5 days later and, one month later, sacrificed by decapitation at 10 a.m. 
Then, pineal glands were removed and placed in perifusion chambers containing Hanks 199 medium. The medium was 
satured with O2/CO2 (95 %/5 %) and its pH was 7.4. Ten independent chambers were immersed in a water bath at 37°C. 
Each pineal gland received medium (flow rate : 0.16 ml/min) through a system of input lines. The fractions were collected 
every 10 min, and immediately frozen at –20°C until Melatonin RIA. Experiments were repeated to obtain up to five ex-
perimental points for each treatment. Tamoxifen (10-9 to 10-7 M) was applied during the entire perifusion period (7 hours). 
Isoproterenol (10-6 M) was applied for 20 min after 3 hours in perifusion. Melatonin concentrations and Areas Under the 
Curves were compared using two-factor ANOVA as well as parametric or nonparametric two-sample methods after test-
ing sample normality.  
 In vehicle treated rats, Tamoxifen treatment, at the concentration of 10-9M, leads to a non significant amplification of the 
Isoproterenol-induced stimulation of Melatonin secretion. 
 In DMBA-treated rats, Tamoxifen treatment leads,starting from 10-9M to a dose- dependent increase (up to 400% in-
crease) of the Isoproterenol-induced stimulation of Melatonin . 
 The results suggest that in addition to the well documented beneficial effects of Tamoxifen at the mammary gland level, 
this E2 antagonist may also have, after DMBA treatment, an additional beneficial effect at the pineal gland level through-
out the stimulation of Melatonin, which exerts an inhibitory action on the induction and on the growth of breast cancers. 
Keywords: Dimethylbenz(a)anthracene, female rat, mammary cancer, melatonin, tamoxifen. 
INTRODUCTION 
 Female Sprague-Dawley rats develop mammary adeno-
carcinoma in response to a single intragastric dose (15 mg) 
of the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) 
[1]. The mechanisms by which DMBA induces mammary 
tumors in rats are well characterised. This carcinogen inter-
acts with rapidly proliferating cells in the terminal end buds, 
forming DNA adducts, which in turn participate in trans-
forming the normal terminal end bud cells to malignant  
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pathways [2-4]. The susceptibility of Sprague-Dawley rats to 
DMBA is maximal at 55-60 days of age and is abolished by 
ovariectomy, suggesting that the inducible action of the car-
cinogen depends on ovarian hormones [5]. 
 Furthermore, the appearance of DMBA-induced adeno-
carcinoma is preceded by a series of disturbances of the Hy-
pothalamo-Pituitary-Gonadal during the latency period. Es-
trous cycles are associated with blunted preovulatory surges 
of LH and FSH [6], increased surges of plasma 17-Estradiol 
[7] and disruption in Hypothalamic Gonadotropin-Releasing 
Hormone (GnRH) and its Pituitary Receptor Gene Expres-
sion patterns [8]. Moreover, ovariectomized rats pre-treated 
5 days before ovariectomy with DMBA, exhibit one month 
later, a blunted LH release in response to in vivo Estradiol 
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replacement and a reduced GnRH release as measured in 
vitro using synaptosomes from the mediobasal hypothalamus 
[9], suggesting a possible direct and long lasting action of 
DMBA at the brain level. Also, a long-term deregulation of 
the circadian and 17-Estradiol-induced LH, prolactin and 
corticosterone secretion was seen after DMBA administra-
tion[10]. Last but not least, Estradiol treatment leads, in a 
dose dependant manner, to a complete blunting of the spon-
taneous and Isoproterenol-induced Melatonin secretion from 
the in vitro perifused pineal gland during the latency period 
[11]. 
 On the other hand, it has been shown that Melatonin 
which is involved in the control of reproduction [12, 13] also 
exerts, in vivo [14-15] and in vitro [16-17], an oncostatic 
activity on the mammary tissue in activating the Estrogen 
Receptor (ER) for DNA binding [18], or in modulating the 
ER mRNA expression [19] or the increase of the ER binding 
activity [20]. Surprisingly, Melatonin has also a strong pre-
ventive effect on the mammary carcinogenesis induced by 
DMBA [21]. 
 In view of the well documented antiestrogenic properties 
of Tamoxifen [22], we therefore examined the long-term 
effects of Tamoxifen on Melatonin secretion induced by Iso-
proterenol from the pineal gland of animals which were 
treated, one month before, by a single administration of 
DMBA. 
MATERIALS AND METHODS 
Animals 
 The animal studies described in this manuscript were 
conducted in accord with accepted standards of human care. 
The study was approved by the authors’ institutional com-
mittee on animal care. 
 Seventy Dawley female rats (Charles River), 49 to 51 
days of age, were used in the present study. 
 They were housed (6-7 animals per cage), under con-
trolled temperature (21 + 1°C). The animal housing room 
diurnal cycle was 12 hours light/12 hours darkness (light on: 
from 7a.m. to 7 p.m.). The animals receive UAR food and 
water ad libidum. 
 After 4 or 5 days of acclimatation, the rats received 15 
mg of DMBA in 1 ml of sesame oil or 1 ml of the vehicle 
alone, on the day of Estrous of the Estrous cycle. All rats 
were treated at 55 days of life, since the induction of the 
mammary cancer is maximal at this time of life [1]. Five 
days after this treatment, the rats were anesthetized with 70 
mg chloral hydrate in 1 ml of saline solution and ovariec-
tomized. Then, they were sacrificed by decapitation one 
month later, and the pineal gland was removed and perfused 
by using previously described perfusion methods [11,23] 
 Briefly, the pineal glands were collected in 1 ml of Me-
dium 199 (Sigma-Aldrich), without phenol red, which con-
tains HANK medium with NaHCO3 (0.35 g/l), BSA (1 g/l) 
and Bacitracine (0.14 g/l), pH 7.4. It was equilibrated with a 
mixture of 95 % O2/5 % CO2. They were perfused in the 
same medium at a flow rate of 0.2 ml/min. One pineal gland 
was used per perfused chamber. 
 Each series of perfusion was performed during 7 hours; 
10 minutes fractions were collected. The perfusion apparatus 
allowed to perifuse 20 pineal glands simultaneously. Ex-
periments were repeated to obtain 5 experimental points for 
each treatment. 
 A 170-min pre-incubation period was required to reach a 
stable level of the concentration of Melatonin. After this pe-
riod, the pineal glands were stimulated with 10-6 M Isopro-
terenol (Sigma), a -adrenergic receptor agonist, for 20 min-
utes between fraction number 17 and 18. This concentration 
of Isoproterenol provokes an almost maximal release of 
Melatonin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Medium concentration of Melatonin (pg/ml + SEM) from perifused pineal gland (n=5) of vehicule-treated (  ) or DMBA-
treated (  ) and ovariectomized rat. Isoproterenol (10-6 M) was added for 20 min during the indicated period ( ). 
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Fig. (2). Medium concentration of Melatonin(pg/ml± SEM) from perifused pineal gland (n=5) of DMBA-treated and ovariectomized rat in 
presence of various concentrations of Tamoxifen applied during the entire perifusion period.Isoproterenol(10-6 M) was added for 20 min dur-
ing the indicated period ( ). 
Measurement of Medium Melatonin 
 The determination of Melatonin concentration was made 
by a previously validated RIA method, without extraction of 
the samples [24]. 
 Briefly, the Rabbit Polyclonal Melatonin Antiserum (AB 
19540) was kindly given to us by Doctor RAVAULT 
(INRA, Nouzilly, France). It was used at a final dilution of 
1/100 000, in a total volume of 500 l. 
 The I125 Melatonin was from NEN (Life Science Products 
Inc. Boston, MA). Melatonin used as standard was from 
Sigma. 
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 The antibody/Antigen complex was isolated by using a 
pony antiserum against Rabbit -Globulins. 
 The limit of sensitivity of the assay,defined as two stan-
dard deviations of melatonin binding was 1 pg/tube. The 
minimum detection level for the assay was between 1 and 2 
pg/tube.The intra- and inter–assay coefficients of variation 
were less than 4 % and 6 %, respectively. 
Statistical Analysis 
 The normality of data was analysed by the Kolmogorov – 
Smirnov and Shapiro Wilk tests. The influence of perifusion 
time and treatment on Melatonin concentrations and Areas 
Under the Curves were analysed with two factor ANOVA 
followed by two-sample comparisons. 
 In the case of samples drawn from gaussian populations, 
the Student’s t or the Welsh tests was used. 
A p value < 0.05 was considered significant. 
RESULTS 
I. Effect of DMBA Treatment on the In vitro Release Of 
Melatonin (Fig. 1) 
 In absence of DMBA treatment, a marked biphasic pat-
tern of Melatonin secretion was observed. Before the appli-
cation of Isoproterenol, a spontaneous secretion of Mela-
tonin, with maximal values by 40-50 min after the beginning 
of the perifusion, was observed. At that time, a 3 fold in-
crease in the concentration of melatonin was observed. After 
the application of isoproterenol, maximal values were seen 
by 60-120 min after the beginning of the application. Again, 
a 3 fold increase in the concentration of melatonin was ob-
served. 
 In presence of DMBA treatment, a marked modification 
of the patterns of the secretion of Melatonin was observed. 
Overall, the pattern was similar to the pattern observed in 
absence of DMBA treatment but mean values were almost 
two times lower than those observed in controls. Before the 
application of Isoproterenol, the spontaneous secretion of 
Melatonin was almost completely abolished. A non signifi-
cant 50 % increase was noted. After the application of Iso-
proterenol, the pattern of secretion of Melatonin follows the 
pattern observed in controls but mean values were again 
lower than those seen in controls. 
 The Area Under the Curve (AUC), expressed as 
pg/ml.mins ( Mean + SEM), was 83216 ±4350 in absence of 
DMBA treatment vs 47020± 4389 in presence of DMBA 
treatment ; the mean values of the DMBA treated group are 
very significantly lower than those from the vehicle treated 
group (p=0.0007 ) 
II Effect of Increasing Concentrations of Tamoxifen 
Upon the Spontaneous and the Isoproterenol -Induced 
Melatonin Secretion (Fig. 2) 
 Fig. (2) shows the in vitro effect of increasing concentra-
tion of Tamoxifen upon the spontaneous and the Isoprotere-
nol-induced Melatonin secretion from the pineal gland of 
DMBA-treated rates. 
 It can be seen, that starting from the concentration of 10-9 
M a significant increase in the secretion of Melatonin in-
duced by Isoproterenol was observed. However, the sponta-
neous secretion was not affected. Clearly, a marked effect 
was seen at the concentration of 10-7M on both the spontane-
ous and the Isoproterenol-induced Melatonin secretion. A 
maximal effect on both parameters was observed at the con-
centration of 10-7M. 
 The Area Under the Curve are given in Table 1. Again, a 
dose -dependent increase in the total amount of Melatonin 
secreted was observed. 
 However, a concentration of 10-9M of Tamoxifen was 
inefficient in stimulating the secretion of Melatonin from the 
pineal gland of non DMBA-treated rats. 
DISCUSSION 
 The results of this study demonstrate that a single intra-
gastric administration of DMBA to Sprague-Dawley female 
rat induces a long term marked stimulation by Tamoxifen of 
the spontaneous and Isoproterenol-induced Melatonin secre-
tion from the pineal gland. On the contrary, we previously 
documented that Estradiol has an opposite effect on Mela-
tonin secretion after DMBA exposure (M.Beau Yon De Jon-
age-Canonico et al., Reference [11]). The results of this 
study are summarized in Fig. (3) and Table 2. It can be seen 
that a complete blunting of the spontaneous and Isoprotere-
nol-induced secretion of Melatonin was observed when Es-
tradiol was applied at the concentration of 10-9 M. A strong 
inhibitory effect was already observed at 10-10 M of Estra-
diol. 
 However, a 10-9M concentration of Estradiol was of a 
non significant effect on Melatonin secretion. 
 The influence of ovarian steroids on Melatonin secretion 
was investigated by several laboratories with conflicting 
results [25-29]. Interestingly enough, pineal melatonin syn-
Table 1. Statistics of the AUC of medium Melatonin Concentrations from the pineal Gland of DMBA treated and ovariectomized Rat, perifused 
for 7 hours with increased Concentrations of Tamoxifen and with Isoproterenol (10-6M) for 20 min. ( mean, sem and significance level p). 
Treatment 
Treatment 
Mean ± SEM 
(pg/ml,mins) 
Control Tamoxifen 10
-9
 M Tamoxifen 10
-8
 M Tamoxifen 10
-7
 M 
Control 56 886 ± 2 900   0.01 ( t ) * 0.05 ( W ) * 0.03 ( W ) * 
Tamoxifen 10-9 M 89 295 ± 8 882 0.01 ( t ) *   0.07 ( t ) 0.02 (t ) * 
Tamoxifen 10-8 M 126 957 ± 24 144 0.05 ( W ) * 0.07 ( t )   0.23 ( t ) 
Tamoxifen 10-7 M 172 118 ± 28 464 0.03 ( W ) * 0.02 (t ) * 0.23 ( t )   
t = Student ; when unequal variances , W = Welch ; * = significant. 
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thesis and release are not altered throughout the estrous cycle 
in females rats(30) but there are changes in noctural mela-
tonin secretion in perimenopausal women which negatively 
h endogenous serum 17 Estradiol: there is a transient 
change in noctural melatonin secretion which be related to 
the existence of a low estrogen environment(31). The influ-
ence of Tamoxifen or others antagonists of ER on Melatonin 
secretion was, to our knowledge,not documented. 
 In vivo, Estradiol might also exert an inhibitory influence 
by inhibiting Norepinephrine release leading to a decrease in 
Melatonin secretion [29]. 
 Very interestingly, the transient and spontaneous release 
of Melatonin has been constantly documented. It consisted in 
a 2 to 3 fold increase in Melatonin secretion which culmi-
nates in our experimental conditions on time 45 min, with a 
return to initial values by 90 min after the start of the perifu-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Medium concentration of Melatonin (pg/ml ± SEM) from perifused pineal gland (n=5) of DMBA-treated and ovariectomized rat in 
presence of various concentrations of E 2 applied during the entire perifusion period.Isoproterenol (10-6 M ) was added for 20 min during the 
indicated Period ( ). From M. Beau Yon De Jonage-Canonico et al. (Ref. [11]). 
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sion. It is assumed that this spontaneous release is due to a 
release of Norepinephrine from surgically sectioned 
Noradrenergic fibbers from the Superior Cervical Ganglion 
[23,25] which innervates the pineal gland. 
 The kinetic characteristics of the Isoproterenol-induced 
Melatonin secretion have been well documented [11,23]. It 
consisted of a 2-3 fold increase in Melatonin concentration 
which culminates by 90 min after the transient addition of 
Isoproterenol into the perifusion medium. The selected con-
centration of Isoproterenol (10-6 M) allows to observe an 
almost maximal release of Melatonin with a return to pres-
timulation concentrations by 4 h after the beginning of the 
stimulation. In DMBA treated rats, both the spontaneous and 
the Isoproterenol-induced release of Melatonin were re-
duced. 
 The presence of receptors for E2 at the pineal level has 
been documented [28]. Nevertheless, the presence of ER 
variants [32] and/or an increase in the affinity of the ER 
might explain the marked efficiency of E2 to inhibit Mela-
tonin secretion and of Tamoxifen to stimulate Melatonin 
secretion from the pineal gland. It might result from a modi-
fication at the genomic level, either at the transcriptional 
level, at the epissage of the primary transcript or at the tra-
duction level of the mature messenger. 
 It is thought that DMBA acts, at the mammary gland 
level, throughout the formation of metabolites and DNA 
adduct [33-34] which will provoke the initiation of the 
mammary carcinogenesis. Also, recent data from our labora-
tory (data not shown) indicate that DMBA cross the blood 
brain barrier, reaches at least steroid receptor rich regions of 
the brain, including the pineal gland, and is able to be locally 
metabolised. It may be envisioned that DNA adducts could 
provoke a cascade of morphological and/or biochemical 
events leading to the long term disruption of the E2 and Ta-
moxifen control after DMBA treatment. 
 It has been shown that pinealectomy enhances and Mela-
tonin inhibits tumor growth of DMBA-treated female rat 
[35-36]. An effect of DMBA on pineal Melatonin biosynthe-
sis, secretion and peripheral metabolism has been docu-
mented [37]. Seven days after DMBA treatment of Female 
Sprague-Dawley rats, nocturnal plasma Melatonin concen-
trations were depressed by 31-37 % [37]. Also, a depression 
of nocturnal circulating Melatonin in patients with Primary 
Breast Cancer has been documented [38-39]. Apparently, 
this decrease in Melatonin concentration is not due to an 
increased peripheral metabolism of Melatonin since both 
nocturnal Melatonin and its main metabolic product 6-
sulfatoxymelatonin were significantly lowered in patients 
with Primary Breast Cancer [39]. Therefore, the decrease in 
nocturnal serum Melatonin concentration is not due to an 
enhanced degradation to 6-sulfatoxymelatonin in the liver 
but must be due to reduced activity, for an unknown reason, 
of the pineal gland [39].Interestingly, it has been shown that 
the administration of Melatonin markedly reduces the per-
centage of tumor-bearing animals after administration of 
DMBA [11]; also, the latency period was increased and the 
number of tumors per tumor-bearing animal was signifi-
cantly reduced by a long term melatonin treatment [11]. 
 In view of the present results and of the well documented 
oncostatic properties of Melatonin, it can be envisioned that 
the long term stimulation of Melatonin secretion by Ta-
moxifen may play an additional protective and curative role 
on breast cancer.Interestingly,it has been documented that 
the treatment of MCF-7 human breast cancer cells in vitro 
with Melatonin increases the sensitivity of these cells to Ta-
moxifen [40]. 
 Taken together, the results show the capacity of ta-
moxifen to stimulate pineal melatonin synthesis and the im-
portance of pineal ER to modulate melatonin secretion and 
thus to affect breast cancer evolution. 
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